Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
American Journal of Clinical Dermatology · 2024-03 · 25 (2) · 299-314
DOI: 10.1007/s40257-024-00846-3 ↗Kurz gefasst
Klinische Studie in der Zeitschrift American Journal of Clinical Dermatology, online erschienen am 23.01.2024. Verfasst von Brett King und 14 weiteren Autor:innen. Beteiligte Einrichtung: Yale School of Medicine, New Haven, CT, USA. Hauptthemen laut MEDLINE: Alopecia Areata, Antineoplastic Agents, Tryptamines. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCATS NIH HHS, Pfizer.
Abstract (Originalsprache)
BACKGROUND: The ALLEGRO phase 2a and 2b/3 studies demonstrated that ritlecitinib, an oral JAK3/TEC family kinase inhibitor, is efficacious at doses of ≥ 30 mg in patients aged ≥ 12 years with alopecia areata (AA). OBJECTIVE: The objective of this study was to evaluate the safety of ritlecitinib in an integrated analysis of four studies in AA. METHODS: Two cohorts were analyzed: a placebo-controlled and an all-exposure cohort. Proportions and study size-adjusted incidence rates (IRs) of adverse events (AEs) of interest and laboratory abnormalities are reported. RESULTS: In the placebo-controlled cohort (n = 881; median exposure: 169 days), the proportion of ritlecitinib-treated patients with AEs was 70.2-75.4% across doses versus 69.5% in the placebo group; serious AEs occurred in 0-3.2% versus 1.9% for the placebo. A total of 19 patients permanently discontinued due to AEs (5 while receiving the placebo). In the all-exposure cohort (n = 1294), median ritlecitinib exposure was 624 days [2091.7 total patient-years (PY)]. AEs were reported in 1094 patients (84.5%) and serious AEs in 57 (4.4%); 78 (6.0%) permanently discontinued due to AEs. The most common AEs were headache (17.7%; 11.9/100 PY), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive test (15.5%; 9.8/100 PY), and nasopharyngitis (12.4%; 8.2/100 PY). There were two deaths (breast cancer and acute respiratory failure/cardiorespiratory arrest). Proportions (IRs) were < 0.1% (0.05/100 PY) for opportunistic infections, 1.5% (0.9/100 PY) for herpes zoster, 0.5% (0.3/100 PY) for malignancies (excluding nonmelanoma skin cancer), and 0.2% (0.1/100 PY) for major adverse cardiovascular events. CONCLUSIONS: Ritlecitinib is well tolerated with an acceptable safety profile up to 24 months in patients aged ≥ 12 years with AA (video abstract and graphical plain language summary available). TRIAL REGISTRIES: ClinicalTrials.gov: NCT02974868 (date of registration: 11/29/2016), NCT04517864 (08/18/2020), NCT03732807 (11/07/2018), and NCT04006457 (07/05/2019).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Yale School of Medicine, New Haven, CT, USA.
- Southern California Dermatology, Santa Ana, CA, USA.
- St John's Institute of Dermatology, King's College London, London, UK.
- Department of Dermatology, Medical University of Warsaw, Warsaw, Poland.
- Rouen University Hospital, INSERM 1234, Normandie University, Rouen, France.
- Skin Centre for Dermatology, Canada Probity Medical Research, Waterloo, ON, Canada.
Förderung
- NCATS NIH HHS
- Pfizer
Zitieren
APA
King, B., Soung, J., Tziotzios, C., Rudnicka, L., Joly, P., Gooderham, M., Sinclair, R., Mesinkovska, N. A., Paul, C., Gong, Y., Anway, S. D., Tran, H., Wolk, R., Zwillich, S. H., & Lejeune, A. (2024). Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program. American Journal of Clinical Dermatology, 25(2), 299-314. https://doi.org/10.1007/s40257-024-00846-3
Vancouver
King B, Soung J, Tziotzios C, Rudnicka L, Joly P, Gooderham M, et al. Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program. American Journal of Clinical Dermatology. 2024;25(2):299-314. doi:10.1007/s40257-024-00846-3
BibTeX
@article{King2024,
author = {King, Brett and Soung, Jennifer and Tziotzios, Christos and Rudnicka, Lidia and Joly, Pascal and Gooderham, Melinda and Sinclair, Rodney and Mesinkovska, Natasha A and Paul, Carle and Gong, Yankun and Anway, Susan D and Tran, Helen and Wolk, Robert and Zwillich, Samuel H and Lejeune, Alexandre},
title = {Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program},
journal = {American Journal of Clinical Dermatology},
year = {2024},
volume = {25},
number = {2},
pages = {299--314},
doi = {10.1007/s40257-024-00846-3}
}
EUVIMED